Solifenacin succinate is a medication used to treat overactive bladder (OAB) symptoms, such as urinary urgency, frequency, and incontinence. The primary active ingredient is solifenacin [1].
When does solifenacin's main patent expire?
The principal patent protecting solifenacin succinate, U.S. Patent No. 5,382,611, expired in 2011 [1]. However, additional patents and exclusivities may have extended market protection for the branded drug, Vesicare.
What other patents are associated with solifenacin?
Beyond the foundational patent, numerous other patents have been issued related to solifenacin, covering various aspects such as specific salt forms, manufacturing processes, and methods of use. DrugPatentWatch.com tracks these patents, offering insights into their expiration dates and potential impact on generic entry [1]. For example, patents related to crystalline forms of solifenacin succinate have been a significant focus in patent litigation and market exclusivity discussions.
Can generic versions of solifenacin be sold before patent expiry?
Generic manufacturers may attempt to enter the market before the expiry of all relevant patents by challenging existing patents or developing non-infringing formulations or processes. The U.S. Food and Drug Administration (FDA) approves generic drugs based on bioequivalence to the brand-name drug, but market exclusivity can be influenced by patent status and any associated litigation [1].
Who manufactures solifenacin and its generics?
The original branded version of solifenacin succinate is marketed as Vesicare by Astellas Pharma. Following patent expiries and challenges, multiple pharmaceutical companies have developed and market generic versions of solifenacin succinate. These include manufacturers such as Teva Pharmaceuticals, Mylan, and Aurobindo Pharma, among others [1].
What is the mechanism of action for solifenacin?
Solifenacin is a muscarinic receptor antagonist. It works by blocking the action of acetylcholine on muscarinic receptors in the bladder muscle. This blockade reduces involuntary contractions of the bladder, thereby increasing bladder capacity and decreasing urinary urgency and frequency [1].
What are the common side effects of solifenacin?
Commonly reported side effects of solifenacin include dry mouth, constipation, blurred vision, and indigestion. Less common but potentially serious side effects can include urinary retention, angioedema, and cognitive impairment. Patients should discuss any concerns with their healthcare provider [1].
How does solifenacin compare to other OAB medications?
Solifenacin belongs to the class of anticholinergic medications used for OAB. Other drugs in this class include oxybutynin, tolterodine, and darifenacin. Each medication has a different receptor selectivity and side effect profile. Some newer OAB treatments, like mirabegron, are beta-3 adrenergic agonists and work through a different mechanism, potentially offering an alternative for patients who cannot tolerate anticholinergics [1].
What is the pricing and insurance coverage for solifenacin?
The cost of Vesicare and its generic equivalents can vary significantly based on dosage, quantity, pharmacy, and insurance coverage. Branded medications are typically more expensive than generics. Many insurance plans provide coverage for solifenacin, but co-pays and deductibles will apply. Online resources and patient assistance programs may offer cost-saving options [1].